Ascendis Pharma AS (ASND)
122.64
-1.74
(-1.40%)
USD |
NASDAQ |
Nov 21, 16:00
122.73
+0.09
(+0.07%)
After-Hours: 20:00
Ascendis Pharma Gross Profit Margin (Quarterly): 80.63% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 80.63% |
| June 30, 2024 | 68.15% |
| March 31, 2024 | 92.11% |
| December 31, 2023 | 85.87% |
| September 30, 2023 | 84.62% |
| June 30, 2023 | 72.72% |
| Date | Value |
|---|---|
| March 31, 2023 | 86.24% |
| December 31, 2022 | 77.67% |
| September 30, 2022 | 88.93% |
| June 30, 2022 | 82.37% |
| March 31, 2022 | 37.81% |
| December 31, 2021 | 28.06% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
28.06%
Minimum
Dec 2021
92.11%
Maximum
Mar 2024
73.77%
Average
81.50%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Novo Nordisk AS | 84.14% |
| Evaxion Biotech AS | -- |
| Trinity Biotech PLC | 35.03% |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -48.84% |
| Return on Invested Capital | -89.94% |
| Profit Margin (Quarterly) | -171.5% |
| Operating Margin (Quarterly) | -167.3% |
| Return on Net Operating Assets | -96.45% |